Association of adjuvant chemotherapy regimen with serial CA-125 kinetics (KELIM framework) and progression-free survival after cytoreductive surgery for ovarian cancer: a retrospective cohort study

Authors

Institutions

Publication Details

Journal
ONCOLOGIE
Published
2026-03-03
DOI
https://doi.org/10.1515/oncologie-2025-0535
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of adjuvant chemotherapy regimen with serial CA-125 kinetics (KELIM framework) and progression-free survival after cytoreductive surgery for ovarian cancer: a retrospective cohort study

Razan Amjad, Abdulkareem Fayoumi, Dahlia Mirdad, Wael y Alsayed et al.
ONCOLOGIE
Ovarian cancer diagnosis and treatment
article

Association of adjuvant chemotherapy regimen with serial CA-125 kinetics (KELIM framework) and progression-free survival after cytoreductive surgery for ovarian cancer: a retrospective cohort study

Razan Amjad, Abdulkareem Fayoumi, Dahlia Mirdad, Wael y Alsayed, Ahmad Alwazzan, Humaira Waseem, Zayd Jastaniah, Reyouf Abdulsalam Almughamsi, Rayyan Hasanain, Amber Hassan, Hisham Nasief, Huda Altoukhi
article en

Abstract

No abstract available for this paper.
ONCOLOGIE
INTI International University (MY), King Abdulaziz University (SA), University of Jeddah (SA), European School of Molecular Medicine (IT), King Fahad Hospital Jeddah (SA)
Good health and well-being
Openalex Percentile: Top 32%
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.